To learn more about locating your business at the Illinois Science + Technology Park, click here.

With injectable drug products, there are many different fac­tors that must be carefully evaluated to develop an optimal asep­tic manufacturing strategy. Among these many considerations, there is one critical decision that every CDMO can help their cus­tomer navigate: Which aseptic filling line is right for the product?

Container type has historically been one of the most decisive factors, as aseptic filling facilities have long relied on container-specific platforms designed to process bulk vials, syringes, or car­tridges sterilized on-site. Today, however, a growing number of drug developers and drug manufacturers are shifting their atten­tion to ready-to-use (RTU) container platforms: increasingly for­mat-agnostic systems that process pre-sterilized containers delivered in fill-ready nest/tub or tray configurations. These plat­forms offer an added level of flexibility and efficiency that has made them a desirable option for many injectable drug owners.

To access the entire article, click here.

Vetter is well-prepared to harness this trend, with ongoing investment in a range of RTU-specialized resources and infrastructure. At the same time, Vetter is also pursuing the kind of strategic, forward-thinking sustainability strategies that our industry will need to address the environmental impact of RTU con­tainer platforms. With the right sustainability, regulatory, and standardization solutions in place, Vetter is confident that these tech­nologies can help customers achieve the efficiency, sustain­ability, and quality we all hope to see in the biopharmaceutical value chain

Paul M. Peloso, MD, joined COUR in 2024 as Chief Medical Officer where he leads the company’s clinical development programs. Prior to joining COUR, Dr. Peloso served as Chief Medical Officer for ACELYRIN, Inc., a biopharma company focused on providing life-changing new treatment options for patients by employing a strategy of identifying, acquiring and accelerating development and commercialization of promising drug candidates. While at ACELYRIN, Dr. Peloso was responsible for global clinical development of the company’s pipeline of products, with an initial focus in immunology.

Before ACELYRIN, Dr. Peloso was vice president and therapeutic head for rheumatology of Horizon Therapeutics, where he was responsible for advancing the company’s pipeline of first-in-class rare disease medicines including, notably KRYSTEXXA® until its acquisition by Amgen in 2023. Prior to this role, Dr. Peloso served as group medical director for both AbbVie and Merck, where he leveraged his extensive experience in biologics, small molecules, and medical devices.

Among Dr. Peloso’s global clinical and regulatory achievements across his career, he helped develop and ultimately secure approvals for ORILISSA® (elagolix), ILUMYA™ (tildrakizumab), Arcoxia® (etoricoxib), and Enbrel® (etanercept). Dr. Peloso has also led a broad range of successful filings in numerous therapeutic areas that have led to approvals by the U.S. Food and Drug Administration, European Medicines Agency and in the Asian and Latin American markets

To read the entire announcement, click here. .

“We are delighted to welcome Dr. Peloso during this time of significant growth at COUR,” said John J. Puisis, founder, president, and chief executive officer of COUR. “The addition of Dr. Peloso to our management team comes on the heels of our successful fundraising earlier this year, which will allow us to further develop our clinical-stage pipeline as we advance into Phase 2 clinical studies with our lead program in Myasthenia Gravis as well as advance our Type 1 Diabetes program into the clinic later this year. We look forward to benefiting from Dr. Peloso’s significant expertise in late-stage clinical development and regulatory approval as we aim to bring transformative solutions to patients in need.."

Endeavor Health builds on long history of personalized medicine leadership with polygenic risk score test.

Endeavor Health, in collaboration with GenomicMD, is among the first in the nation to offer the new PRS test. The test involves a simple blood or saliva sample that is analyzed in a lab using cutting-edge research to compare your DNA against a data bank of population genetics.

You receive a “score” that tells you how high your relative risk is for certain heritable diseases. If you receive any scores that indicate a higher risk, your doctor will follow up with you to determine next steps.

"We are building this next generation of medicine where clinicians can use their patients’ unique genetic blueprint to ensure they get the right screening, the right drug or the right treatment … the first time,” said Peter Hulick, MD, Medical Director of the Mark R. Neaman Center for Personalized Medicine and Division Head for the Center for Medical Genetics, Endeavor Health. To read the entire announcement, click here.

The Illinois Science + Technology Park started with the former corporate headquarters of pharmaceutical giant G.D. Searle and has created a community of scientists, inventors, and innovators. We are dedicated to the cultivation of a multi-cultural environment that will create and sustain businesses from basic research through commercialization. This environment includes world class laboratories, office space and key support amenities.

Why Skokie? The company was located in the Ravenswood area of Chicago. The management was looking for a campus like setting where it could grow through out the second half of the 20th century. The decision to establish its operations in Skokie was driven by various strategic factors, including the area's favorable business environment, proximity to key markets, and access to skilled talent pool. This move not only enhanced the company's operational efficiency but also solidifies its position as a key player in the pharmaceutical industry. Learn more about ISTP.